health

The ambulance service has gone on strike from Monday to Thursday because of a 9.2% drop in staff wages. However, the provision of basic services is guaranteed, such as emergencies – including accidents and intra-hospital journeys – and the transportation of oncology and haemodialysis patients with scheduled treatments. The Catalan Health Ministry and the trade union CCOO showed a disagreement on the strike’s success. According to the Catalan Government, the demonstration was only followed by 8% of the workers on its first day, while the CCOO stated that 90% of the non-essential services have not been provided. The owners of the ambulance providers announced significant salary reductions in July. After talks with unions and the mediation of the Catalan Labour Court, an agreement has not been reached to avoid the strike.

Last week, the Catalan Ombudsman issued a report stating that 4% of children in Catalonia under the age of 16 suffer from food deprivation (50,000 children) and he linked it to the current economic crisis. The Primary Care section of the Catalan Society of Paediatrics refutes the Ombudsman’s report warning that the known cases of undernourished children in Catalonia are due to illness and not to financial problems. They stated there are 750 children with food deprivation and most of whom have chronic diseases that cause malnutrition, such as metabolic disorders, neoplasia or anorexia nervosa. They emphasise that nowadays it is incorrect to talk about children with food deprivation in Catalonia for economic reasons, but they are concerned about the future.

Christian Brander is a researcher at the IrsiCaixa AIDS Research Institute and Scientific Director of HIVACAT, the programme for the development of a HIV vaccine. He graduated from the University of Bern in 1994 with a PhD in Immunology and has spent 13 years at Harvard University focusing on cellular immunity to viral infections.

The Catalan research centre has unveiled a new 625-square-metre space where the Academic Research Organisation (ARO) will be based. The ARO will provide support for clinical trials developed throughout the world regarding quality control, methodological, regulatory, statistical and management aspects. Furthermore, the new space has 7 medical boxes, nursery support and a lab to process the samples, which will provide an integral service for clinical trials. The new facilities will be able to host between 750 and 1,100 patients per year and work on 350 trials. It cost €1.2 million, which came from public funds.

50% of tumours are related to mutations of this gene, according to the researchers. A study developed by the Bellvitge Institute of Biomedical Research (IBIDELL), based in Greater Barcelona, and the University of Cincinnati have discovered the role of the noncoding 5S rRNA molecule. This molecule regulates the P53 Tumour Suppressor Gene, which protects healthy cells from turning into cancerous cells. When the cell functions correctly, the levels of P53 are low and stable, but when something wrong is detected, the levels increase and cause the cell’s death, avoiding the development of a tumour. The director of the study, George Thomas, explained that understanding how the P53 works and regulates itself is extremely important since “more than half of the tumours present mutations of this gene”.

The healthcare tourism sector is growing. Russian, British and German visitors make the most of their holiday trip by visiting specialists, passing medical tests or undergoing a surgical operation. As a response to this, a private medical center in Girona has announced that it will invest more than €1 million to profit from healthcare tourism.

Between the 11th and 13th of March, Barcelona will host the spring meeting of Bio-Europe, the continent’s largest partnering conference of the global biotechnology industry, for the second time. 1,300 biomedical companies will participate in the event, with more than 2,000 delegates and executives. 60 out of the 100 Spanish companies attending are from Catalonia. In the last decade, Catalonia, particularly the Greater Barcelona area, has become the most important centre in Southern Europe within the biomedical field and one of the main centres internationally. Barcelona’s Deputy Mayor for Economic Affairs, Sònia Recasens, praised the importance of the event as it boosts those “added-value sectors that are strategic for the city’s economic growth”.

The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in 2012 and almost doubled its sales compared to the 2011 figures. The company’s net profit last year quadruples that of 2011. The good results are due to a significant reduction in debt levels and Grífols’ penetration into the United States market. Besides, this week it announced it bought for €37 million the 60% of Progenika Biopharma’s capital, a Basque biotechnology company specialised in the design of diagnostic tests.

The Catalan Institute of Oncology (ICO) has introduced a world pioneering technique which allows four out of five patients who cannot undergo surgery to survive the illness. This technique causes less after-effects than the traditional radiotherapy. Furthermore, statistics show that with the regular treatment, two thirds of these patients die. However, Ferran Gadea, the Head of the Radiotherapy and Oncology Service, says that the best option to cure a lung cancer is still to undergo the operation when possible.

The technique started in Catalonia in 2007 and by 2011 it was practiced on 40% of patients with renal failure. The Catalan Health Ministry hopes to cover 100% of the cases within the next 5 to 10 years. In the United States it started being used a year ago as they were waiting for clinical results to expand its use. Now, a clinical study on 900 patients from 27 different Catalan centres has proved that the technique reduces mortality by 30% on patients with kidney failure within the first three years. In addition, it improves quality of life, reduces hospitalisations by 22% and it also makes hypotension episodes drop by 28%.

Researchers from the Universitat Autònoma de Barcelona (UAB) have managed to completely cure dogs with type 1 diabetes through a single session of gene therapy. It is the first time ever that the effectiveness of a treatment against this illness in large animals has been proved in the world. This achievement opens the door to being able to translate a similar therapy to humans and cure type 1 diabetes, which currently has no cure and means that patients have to control their blood insulin levels for their whole lives through hormone injections, as untreated it can be fatal. Diabetes mellitus type 1 is an autoimmune illness that destroys the cells of the pancreas that produce insulin, an essential hormone in the process of transforming glucose into energy for the body’s cells.

A better use of body organs has led to an increase in transplant rates in Catalonia despite a lower number of donors. In 2012, 872 organ transplants were made in Catalan hospitals and waiting lists were reduced by 4.6%. Lung transplants increased by 35% and heart donors increased by 18.7%.

According to experiments tested on mice, Catalan scientists have affirmed that the stem cells located in the human umbilical chord, which are multipotential and therefore can become different types of cells, can be used to regenerate the tissue affected by a heart attack or a stroke. Until now the only way to recover the damaged tissue was through pharmacological treatment or a heart transplant.

An international study with the participation of the Hospital Clínic IDIBAPS, which is a leading research centre at a world level on AIDS/HIV and other common diseases, has proved that an anti-retroviral treatment carried out just after the infection delays the damage to the patient’s immune system and reduces the risk of transmission. The results of clinical tests on 366 infected individuals confirmed that the sooner and longer an initial anti-retroviral treatment is applied, the later the life-long treatments have to start. However, despite the results, researchers insist that is still too soon to change the current AIDS/HIV treatment protocols.

The IDIBAPS has opened a new research centre of more than 5,000 m2, where more than 200 researchers split into 23 different research groups will be working. It will focus its work on oncology, neurosciences and cell therapies along with infectious, respiratory, cardiovascular and renal diseases. The new centre has been possible thanks to a donation by the private foundation CELLEX, sponsored by Pere Mir. The new centre is located within the University of Barcelona’s Faculty of Medicine, which is integrated into the prestigious Hospital Clínic. The centre consolidates Catalonia, and in particular Barcelona, as one of Europe’s main biomedical poles.